Organization
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
11 abstracts
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,
Abstract
Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,
Abstract
International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.Org: Dana-Farber Cancer Institute, Institut Jules Bordet, Université Libre de Bruxelles, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Centro de Pesquisa Clínica Hospital São Lucas da PUCRS,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Winship Cancer Institute of Emory University, Seoul National University Hospital, IRCCS Ospedale San Raffaele,
Abstract
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC,
Abstract
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,
Abstract
A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.Org: National Cancer Center Hospital East, Chiba, Japan, Samsung Medical Center, Seoul, seoul, South Korea, NEXT Oncology, San Antonio, TX, National Cancer Center Hospital, Tokyo, Japan, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.Org: University of California, San Francisco, Miami Cancer Institute, Baptist Health South Florida, Mayo Clinic, Rush University Medical Center,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I-SPY2.Org: University of California, San Francisco Department of Surgery, University of California, San Francisco, Susan G. Komen, UCSF Breast Science Advocacy Core, Mayo Clinic - Department of Surgical Oncology,